Weidong Zhang

发表

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

E. Peeva, M. Gooderham, S. Forman, 2019, JAMA dermatology.

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis

K. Page, E. Peeva, M. Dowty, 2018, Journal of clinical pharmacology.

Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials

Xiaowen Jiang, Weidong Zhang, Jingjing Gu, 2022, Cancer Immunology, Immunotherapy.

544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)

E. Peeva, B. King, M. Dowty, 2019, Journal of Investigative Dermatology.

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.

E. Peeva, B. King, R. Sinclair, 2021, Journal of the American Academy of Dermatology.

Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib

J. Silverberg, V. Sikirica, J. Cappelleri, 2021, Dermatitis : contact, atopic, occupational, drug.

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials

Guanhong Huang, Weidong Zhang, Jingjing Gu, 2021, Frontiers in Pharmacology.

An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge

Daniel Nilsson, Peter Szolovits, Karen Eilbeck, 2014, Genome Biology.

Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals

Peter K. Joshi, J. Danesh, R. Mägi, 2020, Nature Metabolism.

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

X. Mu, J. Larkin, R. Motzer, 2019, Journal of Clinical Oncology.

Genomic evaluation of circulating proteins for drug target characterisation and precision medicine

J. Danesh, R. Mägi, A. Morris, 2020, bioRxiv.

Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis: TYK2/JAK1 inhibitor in plaque psoriasis.

E. Peeva, M. Suárez-Fariñas, C. Banfield, 2020, The Journal of investigative dermatology.

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.

E. Peeva, B. King, M. Dowty, 2021, The Journal of allergy and clinical immunology.

Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD

M. Lebwohl, J. Cappelleri, E. Peeva, 2020, Dermatology and Therapy.

Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn’s Disease

Steven W. Martin, R. Clare, Baohong Zhang, 2017, Journal of Crohn's & colitis.